(ELV) Elevance Health - Ratings and Ratios
Health Plans, Pharmacy Services, Specialty Insurance, Care Management
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 32.8% |
| Value at Risk 5%th | 50.4% |
| Relative Tail Risk | -6.57% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.47 |
| Alpha | -22.28 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.503 |
| Beta | 0.135 |
| Beta Downside | 0.103 |
| Drawdowns 3y | |
|---|---|
| Max DD | 50.38% |
| Mean DD | 17.68% |
| Median DD | 13.78% |
Description: ELV Elevance Health September 26, 2025
Elevance Health, Inc. (NYSE: ELV) is a U.S. health-benefits company organized into four segments-Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It delivers a broad portfolio of health plans (individual, employer-group, Medicare, Medicaid, and Federal Employee Program) and supplemental products such as dental, vision, and stop-loss insurance, while also operating a full-service pharmacy business that includes home delivery, specialty pharmacy, formulary management, and infusion services. Through its HealthOS platform, Elevance provides data-driven care-management tools, behavioral health, virtual care, payment-integrity solutions, and post-acute services, all under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands.
Key recent metrics underline the company’s scale and growth trajectory: FY 2023 revenue reached approximately $152 billion, with a medical loss ratio (MLR) of 86.5%-a benchmark for cost efficiency in managed care. Enrollment in Medicare Advantage grew 9% YoY, reflecting the aging U.S. population, while the pharmacy segment saw a 5% increase in specialty drug spend, driven by rising prevalence of chronic conditions. Sector-wide, inflationary pressure on medical services and ongoing regulatory reforms (e.g., ACA adjustments and Medicaid expansion in several states) are primary drivers of both premium growth and cost-containment initiatives.
For a deeper, data-rich analysis of Elevance Health’s valuation and risk profile, you may find ValueRay’s platform useful as a next step in your research.
ELV Stock Overview
| Market Cap in USD | 74,514m |
| Sub-Industry | Managed Health Care |
| IPO / Inception | 2001-01-02 |
| Return 12m vs S&P 500 | -27.8% |
| Analyst Rating | 4.41 of 5 |
ELV Dividends
| Metric | Value |
|---|---|
| Dividend Yield | 2.63% |
| Yield on Cost 5y | 2.91% |
| Yield CAGR 5y | 14.45% |
| Payout Consistency | 100.0% |
| Payout Ratio | 22.3% |
ELV Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | -13.28% |
| CAGR/Max DD Calmar Ratio | -0.26 |
| CAGR/Mean DD Pain Ratio | -0.75 |
| Current Volume | 1173.8k |
| Average Volume | 1449.6k |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (5.53b TTM) > 0 and > 6% of Revenue (6% = 11.69b TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 2.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.75% (prev 7.58%; Δ 4.18pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 4.91b <= Net Income 5.53b (YES >=105%, WARN >=100%) |
| Net Debt (-7.78b) to EBITDA (10.02b) ratio: -0.78 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (225.8m) change vs 12m ago -3.13% (target <= -2.0% for YES) |
| Gross Margin 50.46% (prev 27.94%; Δ 22.52pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 162.8% (prev 149.3%; Δ 13.51pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.16 (EBITDA TTM 10.02b / Interest Expense TTM 1.38b) >= 6 (WARN >= 3) |
Altman Z'' 3.11
| (A) 0.19 = (Total Current Assets 63.78b - Total Current Liabilities 40.88b) / Total Assets 122.75b |
| (B) 0.29 = Retained Earnings (Balance) 35.59b / Total Assets 122.75b |
| (C) 0.07 = EBIT TTM 8.48b / Avg Total Assets 119.64b |
| (D) 0.45 = Book Value of Equity 35.05b / Total Liabilities 78.67b |
| Total Rating: 3.11 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 71.89
| 1. Piotroski 7.0pt |
| 2. FCF Yield 5.65% |
| 3. FCF Margin 1.93% |
| 4. Debt/Equity 0.02 |
| 5. Debt/Ebitda -0.78 |
| 6. ROIC - WACC (= 2.88)% |
| 7. RoE 12.91% |
| 8. Rev. Trend 92.62% |
| 9. EPS Trend -0.69% |
What is the price of ELV shares?
Over the past week, the price has changed by -1.26%, over one month by -8.01%, over three months by +4.48% and over the past year by -18.83%.
Is ELV a buy, sell or hold?
- Strong Buy: 13
- Buy: 5
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ELV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 386.1 | 20% |
| Analysts Target Price | 386.1 | 20% |
| ValueRay Target Price | 318 | -1.2% |
ELV Fundamental Data Overview November 19, 2025
P/E Trailing = 13.479
P/E Forward = 11.534
P/S = 0.3825
P/B = 1.6475
P/EG = 0.9454
Beta = 0.532
Revenue TTM = 194.82b USD
EBIT TTM = 8.48b USD
EBITDA TTM = 10.02b USD
Long Term Debt = 31.17b USD (from longTermDebt, last quarter)
Short Term Debt = 929.0m USD (from shortTermDebt, last quarter)
Debt = 929.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -7.78b USD (from netDebt column, last quarter)
Enterprise Value = 66.73b USD (74.51b + Debt 929.0m - CCE 8.71b)
Interest Coverage Ratio = 6.16 (Ebit TTM 8.48b / Interest Expense TTM 1.38b)
FCF Yield = 5.65% (FCF TTM 3.77b / Enterprise Value 66.73b)
FCF Margin = 1.93% (FCF TTM 3.77b / Revenue TTM 194.82b)
Net Margin = 2.84% (Net Income TTM 5.53b / Revenue TTM 194.82b)
Gross Margin = 50.46% ((Revenue TTM 194.82b - Cost of Revenue TTM 96.51b) / Revenue TTM)
Gross Margin QoQ = 14.18% (prev 15.62%)
Tobins Q-Ratio = 0.54 (Enterprise Value 66.73b / Total Assets 122.75b)
Interest Expense / Debt = 37.78% (Interest Expense 351.0m / Debt 929.0m)
Taxrate = 15.58% (219.0m / 1.41b)
NOPAT = 7.16b (EBIT 8.48b * (1 - 15.58%))
Current Ratio = 1.56 (Total Current Assets 63.78b / Total Current Liabilities 40.88b)
Debt / Equity = 0.02 (Debt 929.0m / totalStockholderEquity, last quarter 43.95b)
Debt / EBITDA = -0.78 (Net Debt -7.78b / EBITDA 10.02b)
Debt / FCF = -2.07 (Net Debt -7.78b / FCF TTM 3.77b)
Total Stockholder Equity = 42.87b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.51% (Net Income 5.53b / Total Assets 122.75b)
RoE = 12.91% (Net Income TTM 5.53b / Total Stockholder Equity 42.87b)
RoCE = 11.45% (EBIT 8.48b / Capital Employed (Equity 42.87b + L.T.Debt 31.17b))
RoIC = 9.70% (NOPAT 7.16b / Invested Capital 73.75b)
WACC = 6.82% (E(74.51b)/V(75.44b) * Re(6.51%) + D(929.0m)/V(75.44b) * Rd(37.78%) * (1-Tc(0.16)))
Discount Rate = 6.51% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -2.14%
[DCF Debug] Terminal Value 77.92% ; FCFE base≈2.61b ; Y1≈2.54b ; Y5≈2.57b
Fair Price DCF = 205.3 (DCF Value 45.63b / Shares Outstanding 222.2m; 5y FCF grow -3.53% → 3.0% )
EPS Correlation: -0.69 | EPS CAGR: 5.31% | SUE: 1.95 | # QB: 1
Revenue Correlation: 92.62 | Revenue CAGR: 10.03% | SUE: 1.33 | # QB: 5
Additional Sources for ELV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle